More Noxopharm Ltd. news
Noxopharm Ltd.ASX: NOX

Abscopal Responses Achieved in Prostate Cancer

Apr 29, 2020 at 8:33 PM EDT · Issued by Noxopharm Ltd.

Filed with ASX · Apr 29, 2020 at 8:33 PM EDT

On 6ix: 6ix.com/news/abscopal-responses-achieved-in-prostate-cancer

Noxopharm Ltd. has released a press release.

View Attachment

6ix hasn’t read this filing yet.

Noxopharm Ltd. on 6ix

Story so far

  • LuPIN Prostate Cancer Trial Fully RecruitedMar 3, 2020
  • Positive DARRT-1 Data in Late-Stage Prostate CancerDec 2, 2019
  • More Evidence that Veyonda Enhances RT in Prostate CancerAug 28, 2019

Earlier from Noxopharm

  • Pipeline Expands With Potential New Brain Cancer TreatmentApr 22, 2020
  • Approval to be sought for COVID-19 Clinical Study in U.S.Apr 20, 2020
  • Noxopharm Investigating Potential COVID-19 TreatmentMar 31, 2020
  • Veyonda Awarded First Allowed Patent ApplicationMar 16, 2020
  • LuPIN Prostate Cancer Trial Fully RecruitedMar 2, 2020

Later from Noxopharm

  • Noxopharm March 2020 Quarterly Report & Appendix 4CApr 30, 2020
  • $7.9 Million Fully Underwritten Entitlement Offer AnnouncedMay 12, 2020
  • Entitlement Offer ProspectusMay 13, 2020
  • FDA allows Veyonda Pre-IND Submission for COVID-19May 19, 2020
  • ASCO 2020 Highlights NOX66 Potential in Late-Stage CancerMay 31, 2020
All Noxopharm news releases↗

Follow Noxopharm into a list and get an email when it puts out news.

Follow Noxopharm
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer